Cargando…
Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab
BACKGROUND: Codrituzumab, a monoclonal antibody targeting an oncofetal protein glypican-3 (GPC3) expressed on cell surface of hepatocellular carcinoma (HCC) induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth in preclinical studies. Based on this mechanism, tumor GPC3 e...
Autores principales: | Chen, Gong, Chen, Ya-Chi, Reis, Bernhard, Belousov, Anton, Jukofsky, Lori, Rossin, Christine, Muehlig, Axel, Xu, Chao, Essioux, Laurent, Ohtomo, Toshihiko, Di Laurenzio, Laura, Puig, Oscar, Lee, Ray |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828203/ https://www.ncbi.nlm.nih.gov/pubmed/29535817 http://dx.doi.org/10.18632/oncotarget.23830 |
Ejemplares similares
-
Case-control Indian buffet process identifies biomarkers of response to Codrituzumab
por: Pradier, Melanie F., et al.
Publicado: (2019) -
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
por: Carrasquillo, Jorge A., et al.
Publicado: (2018) -
Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3
por: Arulanandam, Antonio, et al.
Publicado: (2023) -
GPC-3 in hepatocellular carcinoma: current perspectives
por: Wu, Yongle, et al.
Publicado: (2016) -
IMMU-16. TARGETING GLYPICAN 2 (GPC2) ON PEDIATRIC MALIGNANT BRAIN TUMORS WITH MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2021)